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tional study of schizophrenic patients who commence RLAI.
Data collected retrospectively (12 months) and prospectively (2
years) includes: patient demographics, medications, hospitalisa-
tions, Clinical Global Impression-Severity (CGI-S), GAF and
adverse events. A general linear model (GLM) was used to deter-
mine the impact of baseline characteristics on GAF improvement
over 12 months. RESULTS: Data from 399 patients from 15 psy-
chiatric services were available for this analysis. The average age
was 38.9 ± 13.2 years (mean ± SD), the mean duration of illness
was 12.0 ± 9.6 years, and 68% were male. The baseline CGI-S
was 4.5 ± 1.0 and GAF was 42.4 ± 14.1. The greatest improve-
ments in GAF score occurred in the ﬁrst 3-months following
switch to RLAI, however, signiﬁcant improvements also occurred
between 3- and 6-months (baseline: 42.8 ± 14.3; 3-months 50.3
± 15.5; 6-months 53.0 ± 15.3, p < 0.001 [0–3 months, and 3–6
months], n = 328). Those patients with baseline GAF scores less
than 30 were more likely to show greater improvements in their
GAF functioning over the 12-month period (GLM coefﬁcient
28.4 [CI: 22.2–34.7, p < 0.001]), as were patients with baseline
GAF scores of 30–60 (GLM coefﬁcient 14.5 [CI: 8.8–20.1, p <
0.001]). Patients whose last does of RLAI was 25 mg and who
stayed on RLAI for 12-months were more likely to have positive
changes in their GAF over the 12-month period (GLM coefﬁ-
cient 5.3 [CI: 1.8–8.8 and 5.0 [CI: 1.7–8.4, p ∼ 0.003], respec-
tively). CONCLUSIONS: Patients with a low GAF score at
baseline, and those who stayed on 25 mg of RLAI are more likely
to show positive improvements in GAF functioning when treated
over a 12-month period. The most signiﬁcant improvements in
functioning are seen in the ﬁrst six months of treatment.
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OBJECTIVE: To obtain a carer’s perspective on the valuation of
eight schizophrenia-related health states using two multi-
attribute utility instruments, the Assessment of Quality of Life
Questionnaire (AQoL), and the EQ5D. METHODS: Eight schiz-
ophrenia-related health state scenarios based on severity of
symptoms and medication side effects were presented to 64
carers of patients with schizophrenia in face-to-face question-
naires. Scenarios were: (A) “good” function with no movement
disorders (extrapyramidal symptoms); (B) “good” function with
movement disorders; (C) “poor” function with no movement
disorders; (D) “poor” function with movement disorders; (E)
hospitalised relapse with no movement disorders; (F) hospi-
talised relapse with movement disorders; (G) post-hospitalisation
with no movement disorders; and (H) post-hospitalisation with
movement disorders. The carers valued each health state using
the AQoL and the EQ5D from the carer and patient perspec-
tives. RESULTS: When carer’s were asked to assess their quality
of life when the person they cared for was in the various health
states, the mean utility values from the AQoL ranged from 0.56
± 0.26 (SD), for Scenario A, to 0.22 ± 0.25, for Scenario F. Mean
utility values for the health states from the EQ5D ranged from
0.76 ± 0.19, for Scenario A, to 0.29 ± 0.42, for Scenario F. When
the carer’s were asked to assess the health state scenarios from
a patient’s perspective, the mean utility values from the AQoL
ranged from 0.37 ± 0.23, for Scenario A, to 0.04 ± 0.19, for Sce-
nario F. Mean utility values for the health states from the EQ5D
ranged from 0.70 ± 0.28, for Scenario A, to 0.03 ± 0.43, for Sce-
nario F. CONCLUSION: From both perspectives, the rank order
of utility values was consistent with the severity of symptoms,
with more severe symptoms producing lower scores. Scenarios
that involved patients experiencing extrapyramidal symptoms or
hospitalisation produced lower utility values.
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OBJECTIVE: To evaluate if the reimbursement of simvastatin is
justiﬁed in the secondary and primary prevention of coronary
heart disease (CHD) in Poland in 2006. METHODS: Life-table
method in secondary prevention and Markov model in primary
prevention were used. Population characteristics and outcomes
were based on 4S and HPS trials. The analysis in the primary
prevention were performed in two groups with 3% and 5% 5-
year risk of cardiovascular death (CVD) to comply with EURO-
SCORE algorithm. Direct costs of CHD and stroke were
projected over lifetime from Polish National Health Fund per-
spective. Costs, epidemiological data and quality of life weights
(primary prevention) were derived from published sources. Costs
and effects were discounted at 5% annually. RESULTS: LYG in
the secondary prevention was calculated as €365 for 58-year old
men and €613 for 60-year old women. Cost of QALY in the
primary prevention ranged from €2154 for 50-year old men to
€2595 for 65-year old men in the group with 3% risk and from
€1544 to €1796 for 5% risk, well within implicit limits at
roughly €15,000. Results for women were very close to men but
were less robust due to uncertainty in preventing CVD death.
CONCLUSION: Reimbursement of simvastatin in Poland is eco-
nomically justiﬁed regardless of age of initiation of The rapy and
sex. Raising the level of reimbursement from current 70% to
100% will increase availability for all, who may beneﬁt from
The rapy but cannot afford co-payment. The analysis may help
to develop guidelines for primary prevention using EURO-
SCORE risk system.
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OBJECTIVES: To compare the effectiveness of statins with
respect to LDL-cholesterol reduction and cholesterol goal attain-
ment in a real life setting. METHODS: From the PHARMO
database (population > 2 million) we selected new statin users
between December 31, 2002 and January 1, 2005 with LDL-
cholesterol measurements both at baseline and follow-up
(between 30 and 365 days after statin initiation). Hospital
admission and pharmacy data were used to allocate individuals
to primary or secondary prevention categories. The effectiveness
of different statins was compared with respect to LDL-C reduc-
tion (linear regression) and 2003 European guideline cholesterol
goal attainment (logistic regression), adjusting for gender, age,
